Septerna (SEPN)
Septerna on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
3.5M
Short interest
settlement 2026-10-15
7.6
Days to cover
-1.2 days vs prior
81.6%
Short share of volume
2026-11-02
2,120
Fails to deliver
settlement 2026-10-14
Mon 9 Nov
Next earnings
estimated date
-$72.2M
Insider flow, 90 days
0 buys, 8 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in SEPN is 3,522,956 shares, up 628,954 shares over the last month. Over the last 48 readings it ranged from 437,539 shares (31 October 2024) to 4,564,114 shares (15 May 2025). At the reported average volume of 462K shares a day that is 7.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/sepn" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 3,522,956 | +13.8% | 461,750 | 7.63 |
| 2026-09-30 | 3,096,190 | +7.0% | 351,889 | 8.80 |
| 2026-09-15 | 2,894,002 | +6.5% | 303,477 | 9.54 |
| 2026-08-31 | 2,718,332 | -5.4% | 355,387 | 7.65 |
| 2026-08-14 | 2,874,690 | -18.1% | 567,939 | 5.06 |
| 2026-07-31 | 3,507,965 | +4.7% | 247,883 | 14.15 |
| 2026-07-15 | 3,350,617 | +6.2% | 585,751 | 5.72 |
| 2026-06-30 | 3,154,131 | +18.3% | 597,752 | 5.28 |
| 2026-06-15 | 2,665,398 | +1.8% | 342,591 | 7.78 |
| 2026-05-29 | 2,617,322 | +9.5% | 275,168 | 9.51 |
| 2026-05-15 | 2,390,125 | +15.6% | 321,901 | 7.43 |
| 2026-04-30 | 2,067,671 | -15.9% | 380,095 | 5.44 |
| 2026-04-15 | 2,457,303 | +12.9% | 304,769 | 8.06 |
| 2026-03-31 | 2,176,719 | +4.8% | 249,285 | 8.73 |
| 2026-03-13 | 2,076,801 | +12.3% | 332,500 | 6.25 |
| 2026-02-27 | 1,848,804 | +3.9% | 329,565 | 5.61 |
| 2026-02-13 | 1,779,031 | -7.6% | 280,601 | 6.34 |
| 2026-01-30 | 1,924,987 | -0.8% | 251,199 | 7.66 |
| 2026-01-15 | 1,941,013 | +36.0% | 319,319 | 6.08 |
| 2025-12-31 | 1,427,098 | +11.7% | 257,564 | 5.54 |
| 2025-12-15 | 1,277,323 | -13.5% | 274,447 | 4.65 |
| 2025-11-28 | 1,477,425 | -23.1% | 404,592 | 3.65 |
| 2025-11-14 | 1,921,591 | -5.1% | 352,486 | 5.45 |
| 2025-10-31 | 2,025,667 | -21.2% | 262,507 | 7.72 |
| 2025-10-15 | 2,571,016 | -16.4% | 442,902 | 5.80 |
| 2025-09-30 | 3,074,377 | -3.0% | 267,550 | 11.49 |
| 2025-09-15 | 3,168,890 | +2.8% | 257,318 | 12.32 |
| 2025-08-29 | 3,082,422 | -2.5% | 212,903 | 14.48 |
| 2025-08-15 | 3,162,368 | -0.4% | 243,303 | 13.00 |
| 2025-07-31 | 3,174,316 | -15.1% | 213,175 | 14.89 |
| 2025-07-15 | 3,740,655 | +4.4% | 305,478 | 12.25 |
| 2025-06-30 | 3,584,250 | -4.8% | 566,831 | 6.32 |
| 2025-06-13 | 3,766,755 | -14.2% | 523,856 | 7.19 |
| 2025-05-30 | 4,391,879 | -3.8% | 850,547 | 5.16 |
| 2025-05-15 | 4,564,114 | +43.0% | 3,858,767 | 1.18 |
| 2025-04-30 | 3,191,104 | -4.6% | 189,585 | 16.83 |
| 2025-04-15 | 3,344,710 | +5.4% | 264,472 | 12.65 |
| 2025-03-31 | 3,173,173 | +6.6% | 271,842 | 11.67 |
| 2025-03-14 | 2,976,192 | +11.2% | 567,914 | 5.24 |
| 2025-02-28 | 2,676,344 | -13.1% | 1,668,164 | 1.60 |
| 2025-02-14 | 3,079,226 | +37.7% | 286,829 | 10.74 |
| 2025-01-31 | 2,236,366 | -7.1% | 211,243 | 10.59 |
| 2025-01-15 | 2,406,260 | -1.8% | 207,420 | 11.60 |
| 2024-12-31 | 2,451,040 | +142.8% | 653,269 | 3.75 |
| 2024-12-13 | 1,009,713 | +33.5% | 265,174 | 3.81 |
| 2024-11-29 | 756,477 | +38.6% | 150,614 | 5.02 |
| 2024-11-15 | 545,717 | +24.7% | 165,676 | 3.29 |
| 2024-10-31 | 437,539 | +100.0% | 368,343 | 1.19 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of SEPN volume is 81.6%, down 8.1 points over the last five sessions. Over the last 30 readings it ranged from 31.8% (20 October 2026) to 89.8% (16 October 2026). The latest reading is 14.7 points above the 30-session average of 66.9%, on 224K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 183K | 224K | 81.6% | 0 |
| 2026-10-30 | 58K | 83K | 70.0% | 1,479 |
| 2026-10-29 | 49K | 70K | 70.0% | 1,775 |
| 2026-10-28 | 121K | 160K | 75.7% | 1,382 |
| 2026-10-27 | 59K | 74K | 79.2% | 2,783 |
| 2026-10-26 | 79K | 89K | 89.7% | 341 |
| 2026-10-23 | 66K | 84K | 78.4% | 0 |
| 2026-10-22 | 42K | 60K | 69.5% | 562 |
| 2026-10-21 | 62K | 85K | 73.0% | 5,500 |
| 2026-10-20 | 60K | 189K | 31.8% | 2,000 |
| 2026-10-19 | 58K | 132K | 44.0% | 466 |
| 2026-10-16 | 54K | 60K | 89.8% | 0 |
| 2026-10-15 | 58K | 75K | 78.1% | 0 |
| 2026-10-14 | 131K | 147K | 89.3% | 0 |
| 2026-10-13 | 121K | 144K | 84.1% | 0 |
| 2026-10-12 | 55K | 105K | 52.6% | 0 |
| 2026-10-09 | 65K | 113K | 57.5% | 5 |
| 2026-10-08 | 135K | 194K | 69.4% | 0 |
| 2026-10-07 | 113K | 190K | 59.5% | 0 |
| 2026-10-06 | 97K | 166K | 58.2% | 0 |
| 2026-10-05 | 55K | 71K | 77.0% | 631 |
| 2026-10-02 | 59K | 100K | 58.7% | 0 |
| 2026-10-01 | 184K | 222K | 82.7% | 0 |
| 2026-09-30 | 48K | 64K | 74.5% | 0 |
| 2026-09-29 | 162K | 281K | 57.8% | 0 |
| 2026-09-28 | 78K | 158K | 49.5% | 30 |
| 2026-09-25 | 58K | 134K | 43.3% | 0 |
| 2026-09-24 | 85K | 153K | 55.6% | 0 |
| 2026-09-23 | 109K | 249K | 43.8% | 0 |
| 2026-09-22 | 112K | 177K | 63.3% | 1,676 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in SEPN is 2,120 shares, up 1,983 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (24 March 2026) to 49,222 shares (20 March 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 2,120 | $36.42 | $77K |
| 2026-10-07 | 137 | $35.67 | $5K |
| 2026-10-01 | 10 | $39.13 | $391 |
| 2026-08-27 | 28 | $40.25 | $1K |
| 2026-08-12 | 25,492 | $47.76 | $1.2M |
| 2026-08-11 | 812 | $38.85 | $32K |
| 2026-08-10 | 7 | $38.83 | $272 |
| 2026-08-07 | 3 | $39.53 | $119 |
| 2026-08-05 | 1,946 | $38.98 | $76K |
| 2026-07-27 | 339 | $33.10 | $11K |
| 2026-07-23 | 25 | $34.20 | $855 |
| 2026-07-20 | 351 | $33.40 | $12K |
| 2026-07-17 | 1 | $31.56 | $32 |
| 2026-06-22 | 77 | $36.17 | $3K |
| 2026-06-12 | 46 | $34.03 | $2K |
| 2026-06-09 | 214 | $30.41 | $7K |
| 2026-06-05 | 16 | $31.37 | $502 |
| 2026-06-04 | 9 | $30.55 | $275 |
| 2026-06-03 | 9 | $29.94 | $269 |
| 2026-05-13 | 6,731 | $24.84 | $167K |
| 2026-05-05 | 2,567 | $24.82 | $64K |
| 2026-04-30 | 21 | $23.45 | $492 |
| 2026-04-21 | 4,332 | $26.86 | $116K |
| 2026-04-20 | 2,999 | $26.13 | $78K |
| 2026-04-14 | 37 | $23.34 | $864 |
| 2026-03-26 | 831 | $24.21 | $20K |
| 2026-03-24 | 1 | $23.78 | $24 |
| 2026-03-23 | 36,736 | $24.18 | $888K |
| 2026-03-20 | 49,222 | $24.28 | $1.2M |
| 2026-03-16 | 14,110 | $25.14 | $355K |
Insider trades
SEC Form 4, newest first. JSONInsiders at SEPN reported 8 open-market sells worth $72.2M in the last 90 days and no open-market buys. Latest filing: Bhatt Elizabeth (President and COO) on 2026-10-15.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | Bhatt Elizabeth | President and COO | Sell | 3K | $37.61 | $109K | 174K |
| 2026-10-15 | Bhatt Elizabeth | President and COO | Sell | 1K | $36.87 | $40K | 177K |
| 2026-10-15 | Bhatt Elizabeth | President and COO | Exercise or conversion | 4K | $6.81 | $27K | 178K |
| 2026-09-01 | Long Daniel D. | SVP, Drug Discovery | Sell | 3K | $37.83 | $126K | 96K |
| 2026-09-01 | Long Daniel D. | SVP, Drug Discovery | Exercise or conversion | 3K | $2.76 | $9K | 100K |
| 2026-08-12 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Sell | 747K | $42.50 | $31.7M | 725K |
| 2026-08-12 | Third Rock Ventures V, L.P. | 10% owner | Sell | 141 | $51.08 | $7K | 6.1M |
| 2026-08-12 | Third Rock Ventures V, L.P. | 10% owner | Sell | 147K | $50.27 | $7.4M | 6.1M |
| 2026-08-12 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Sell | 747K | $42.50 | $31.7M | 4.8M |
| 2026-08-11 | Bhatt Elizabeth | President and COO | Sell | 25K | $44.00 | $1.1M | 174K |
| 2026-08-11 | Bhatt Elizabeth | President and COO | Exercise or conversion | 6K | $2.76 | $17K | 199K |
| 2026-08-11 | Bhatt Elizabeth | President and COO | Exercise or conversion | 19K | $6.81 | $127K | 193K |
| 2026-08-03 | Long Daniel D. | SVP, Drug Discovery | Sell | 2K | $34.68 | $81K | 96K |
| 2026-08-03 | Long Daniel D. | SVP, Drug Discovery | Sell | 1K | $33.98 | $34K | 99K |
| 2026-08-03 | Long Daniel D. | SVP, Drug Discovery | Exercise or conversion | 2K | $2.76 | $4K | 100K |
| 2026-08-03 | Long Daniel D. | SVP, Drug Discovery | Exercise or conversion | 2K | $2.76 | $5K | 98K |
| 2026-07-15 | Bhatt Elizabeth | President and COO | Sell | 4K | $33.99 | $136K | 174K |
| 2026-07-15 | Bhatt Elizabeth | President and COO | Exercise or conversion | 4K | $6.81 | $27K | 178K |
| 2026-07-01 | Long Daniel D. | SVP, Drug Discovery | Sell | 1K | $34.81 | $43K | 96K |
| 2026-07-01 | Long Daniel D. | SVP, Drug Discovery | Sell | 2K | $34.10 | $72K | 98K |
| 2026-07-01 | Long Daniel D. | SVP, Drug Discovery | Exercise or conversion | 3K | $2.76 | $9K | 100K |
| 2026-06-29 | Shaikhly Samira | Chief People Officer | Sell | 2K | $35.18 | $77K | 793 |
| 2026-06-29 | Shaikhly Samira | Chief People Officer | Exercise or conversion | 2K | $6.81 | $15K | 3K |
| 2026-06-22 | Long Daniel D. | SVP, Drug Discovery | Exercise or conversion | 4K | $11.70 | $52K | 111K |
| 2026-06-22 | Long Daniel D. | SVP, Drug Discovery | Sell | 8K | $35.10 | $281K | 103K |
| 2026-06-22 | Long Daniel D. | SVP, Drug Discovery | Sell | 7K | $35.97 | $252K | 96K |
| 2026-06-22 | Long Daniel D. | SVP, Drug Discovery | Exercise or conversion | 11K | $2.76 | $29K | 107K |
| 2026-06-12 | Shaikhly Samira | Chief People Officer | Sell | 6K | $35.08 | $219K | 793 |
| 2026-06-12 | Shaikhly Samira | Chief People Officer | Exercise or conversion | 6K | $11.70 | $73K | 7K |
| 2026-06-01 | Shaikhly Samira | Chief People Officer | Sell | 3K | $29.66 | $86K | 793 |
| 2026-06-01 | Shaikhly Samira | Chief People Officer | Sell | 1K | $28.79 | $39K | 4K |
| 2026-06-01 | Shaikhly Samira | Chief People Officer | Sell | 2K | $27.78 | $47K | 5K |
| 2026-06-01 | Shaikhly Samira | Chief People Officer | Exercise or conversion | 637 | $2.76 | $2K | 7K |
| 2026-06-01 | Shaikhly Samira | Chief People Officer | Exercise or conversion | 943 | $2.76 | $3K | 6K |
| 2026-06-01 | Shaikhly Samira | Chief People Officer | Exercise or conversion | 4K | $1.55 | $7K | 5K |
| 2026-05-26 | Shaikhly Samira | Chief People Officer | Sell | 12K | $30.06 | $355K | 793 |
| 2026-05-26 | Shaikhly Samira | Chief People Officer | Exercise or conversion | 12K | $6.81 | $80K | 13K |
| 2026-04-15 | Bhatt Elizabeth | President and COO | Sell | 326 | $25.86 | $8K | 174K |
| 2026-04-15 | Bhatt Elizabeth | President and COO | Sell | 1K | $25.24 | $28K | 175K |
| 2026-04-15 | Bhatt Elizabeth | President and COO | Sell | 3K | $23.76 | $61K | 176K |
| 2026-04-15 | Bhatt Elizabeth | President and COO | Exercise or conversion | 4K | $6.81 | $27K | 178K |
| 2026-03-02 | Shaikhly Samira | Chief People Officer | Sell | 66K | $28.14 | $1.9M | 793 |
| 2026-03-02 | Shaikhly Samira | Chief People Officer | Sell | 4K | $27.51 | $112K | 67K |
| 2026-03-02 | Shaikhly Samira | Chief People Officer | Exercise or conversion | 5K | $2.76 | $14K | 71K |
| 2026-03-02 | Shaikhly Samira | Chief People Officer | Exercise or conversion | 12K | $2.76 | $32K | 66K |
| 2026-03-02 | Shaikhly Samira | Chief People Officer | Exercise or conversion | 54K | $1.55 | $83K | 55K |
| 2026-02-18 | Bhatt Elizabeth | President and COO | Sell | 2K | $29.58 | $53K | 174K |
| 2026-02-18 | Bhatt Elizabeth | President and COO | Sell | 2K | $28.46 | $63K | 176K |
| 2026-02-18 | Bhatt Elizabeth | President and COO | Exercise or conversion | 4K | $6.81 | $27K | 178K |
| 2025-11-10 | Long Daniel D. | SVP, Drug Discovery | Sell | 4K | $18.06 | $63K | 93K |
| 2025-08-18 | Klein Uwe | SVP, Biological Sciences | Exercise or conversion | 8K | $6.81 | $52K | 23K |
| 2025-08-18 | Klein Uwe | SVP, Biological Sciences | Exercise or conversion | 5K | $2.76 | $14K | 15K |
| 2025-08-18 | Klein Uwe | SVP, Biological Sciences | Exercise or conversion | 10K | $2.76 | $29K | 10K |
| 2025-04-03 | Finer Jeffrey | CEO and President | Exercise or conversion | 5K | $2.76 | $14K | 827K |
| 2025-04-02 | Finer Jeffrey | CEO and President | Exercise or conversion | 50K | $2.76 | $138K | 822K |
| 2025-03-07 | Ezekowitz Alan | Director | Buy | 13K | $6.93 | $92K | 117K |
| 2025-03-06 | Ezekowitz Alan | Director | Buy | 41K | $6.00 | $248K | 104K |
| 2025-03-05 | Ezekowitz Alan | Director | Buy | 38K | $5.82 | $220K | 63K |
| 2025-03-04 | Ezekowitz Alan | Director | Buy | 7K | $6.35 | $48K | 25K |
| 2025-02-27 | Labrucherie Gil M | Chief Financial Officer | Buy | 4K | $5.85 | $22K | 40K |
| 2025-02-27 | Finer Jeffrey | CEO and President | Buy | 3K | $5.80 | $17K | 772K |
| 2025-02-26 | Finer Jeffrey | CEO and President | Buy | 4K | $5.70 | $23K | 769K |
| 2025-02-25 | Labrucherie Gil M | Chief Financial Officer | Buy | 6K | $5.59 | $35K | 36K |
| 2025-02-25 | Finer Jeffrey | CEO and President | Buy | 10K | $5.68 | $57K | 765K |
| 2025-02-24 | Third Rock Ventures GP V, LP | TenPercentOwner | Buy | 19K | $6.00 | $113K | 4.2M |
| 2025-02-21 | Labrucherie Gil M | Chief Financial Officer | Buy | 5K | $5.85 | $29K | 30K |
| 2025-02-21 | Third Rock Ventures GP V, LP | TenPercentOwner | Buy | 428K | $5.94 | $2.5M | 4.2M |
| 2025-02-20 | Labrucherie Gil M | Chief Financial Officer | Buy | 15K | $5.88 | $85K | 25K |
| 2025-02-20 | Third Rock Ventures GP V, LP | TenPercentOwner | Buy | 613K | $5.92 | $3.6M | 3.8M |
| 2025-02-19 | Labrucherie Gil M | Chief Financial Officer | Buy | 11K | $5.51 | $58K | 11K |
| 2024-10-28 | TRV GP V, LLC | TenPercentOwner | Buy | 280K | $18.00 | $5.0M | 3.2M |
| 2024-10-28 | TRV GP V, LLC | TenPercentOwner | Conversion | 2.9M | $0.00 | $0 | 2.9M |
| 2024-10-28 | TRV GP V, LLC | TenPercentOwner | Buy | 371K | $18.00 | $6.7M | 6.2M |
| 2024-10-28 | TRV GP V, LLC | TenPercentOwner | Conversion | 4.8M | $0.00 | $0 | 5.8M |
| 2024-10-28 | Shah Rajeev M. | Director,TenPercentOwner | Buy | 342K | $18.00 | $6.1M | 1.5M |
| 2024-10-28 | Shah Rajeev M. | Director,TenPercentOwner | Buy | 3.8M | $18.00 | $68.9M | 5.5M |
| 2024-10-28 | Shah Rajeev M. | Director,TenPercentOwner | Conversion | 1.1M | price not stated in the filing | not stated | 1.1M |
| 2024-10-28 | Shah Rajeev M. | Director,TenPercentOwner | Conversion | 1.7M | price not stated in the filing | not stated | 1.7M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON15 Form 144 notices on file for SEPN worth $89.1M at the prices reported; 6 in the last 90 days worth $81.5M. Latest: DANIEL LONG filed on 2026-10-01 to sell 10,001 shares ($391K) from 2026-10-01.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-01 | DANIEL LONGOfficer | 10K | $391K | 0.021% | 2026-10-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-10-01 | SAMIRA SHAIKHLYOfficer | 13K | $493K | 0.027% | 2026-10-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-12 | Third Rock Ventures V, L.P.10% Stockholder | 147K | $7.5M | 0.315% | 2026-08-12 | Raymond James & Associates |
| 2026-08-12 | RA Capital Nexus Fund III, L.P.Affiliate | 747K | $36.0M | 1.599% | 2026-08-12 | BTIG LLC |
| 2026-08-12 | RA Capital Healthcare Fund LPaffiliate | 747K | $36.0M | 1.599% | 2026-08-12 | BTIG LLC |
| 2026-08-11 | ELIZABETH P. BHATTOfficer | 29K | $1.1M | 0.062% | 2026-08-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-15 | ELIZABETH P. BHATTOfficer | 4K | $138K | 0.009% | 2026-07-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-26 | JAE KIMOfficer | 2K | $89K | 0.005% | 2026-06-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-22 | DANIEL LONGOfficer | 25K | $904K | 0.055% | 2026-06-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-22 | JAE KIMOfficer | 94K | $3.3M | 0.209% | 2026-06-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-12 | SAMIRA SHAIKHLYOfficer | 8K | $287K | 0.019% | 2026-06-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-26 | SAMIRA SHAIKHLYOfficer | 12K | $335K | 0.026% | 2026-05-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-02 | SAMIRA SHAIKHLYOfficer | 76K | $2.2M | 0.171% | 2026-03-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-18 | ELIZABETH BHATTOfficer | 8K | $242K | 0.018% | 2026-02-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-10 | DANIEL DAVID LONGOfficer | 4K | $63K | 0.008% | 2025-11-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON5 holders report 5% or more of SEPN in their latest filing, 4 on Schedule 13D (active intent). The largest reported stake is RA Capital Management, L.P. at 11.8% of the class (5,525,324 shares), filed 2026-08-14 for an event on 2026-08-12.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13D/Ano. 1 | RA Capital Management, L.P.investment adviser, partnership | 5.5M | 11.8% | 2026-08-12 |
| 2026-08-14 | 13D/Ano. 1 | Peter Kolchinskyparent holding company, individual | 5.5M | 11.8% | 2026-08-12 |
| 2026-08-14 | 13D/Ano. 1 | Rajeev Shahparent holding company, individual | 5.5M | 11.8% | 2026-08-12 |
| 2026-08-14 | 13D/Ano. 1 | RA Capital Healthcare Fund, L.P.partnership | 4.8M | 10.2% | 2026-08-12 |
| 2026-08-14 | 13G/Ano. 3 | DRIEHAUS CAPITAL MANAGEMENT LLCinvestment adviser | 4.4M | 9.8% | 2026-06-30 |
| 2026-02-17 | 13G/Ano. 2 | LAMPERT MARK Nindividual | 1.7M | 3.8% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 2 | BVF PARTNERS L P/ILinvestment adviser, partnership | 1.7M | 3.8% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 2 | BVF INC/ILcorporation | 1.7M | 3.8% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 2 | BVF GP HOLDINGS LLCother entity | 1.6M | 3.6% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 2 | BIOTECHNOLOGY VALUE FUND L Ppartnership | 920K | 2.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 2 | BVF I GP LLCother entity | 920K | 2.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 2 | BVF II GP LLCother entity | 671K | 1.5% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 2 | BIOTECHNOLOGY VALUE FUND II LPpartnership | 671K | 1.5% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 2 | Biotechnology Value Trading Fund OS LPpartnership | 104K | 0.2% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 2 | BVF Partners OS Ltd.corporation | 104K | 0.2% | 2025-12-31 |
13F holders
Tracked managers holding SEPN at their latest 13F. JSON6 of the 30 tracked managers held SEPN at their latest 13F, $12.8M in total at quarter-end prices. Two Sigma Investments is the largest at $7.4M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 221K | $7.4M | 0.01% | +146K |
| Millennium Management | 2026-06-30 | 51K | $1.7M | 0.00% | -74K |
| D. E. Shaw & Co. | 2026-06-30 | 46K | $1.6M | 0.00% | new |
| Renaissance Technologies | 2026-06-30 | 41K | $1.4M | 0.00% | +4K |
| AQR Capital Management | 2026-06-30 | 15K | $516K | 0.00% | +22 |
| Citadel Advisors | 2026-06-30 | 6K | $213K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Septerna in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Septerna (SEPN), SEC CIK 1984086, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-01.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-10.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-15.JSON and CSV
- Company record
- EDGAR filing index for CIK 1984086Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of SEPN is sold short?
3,522,956 shares were held short at the 2026-10-15 settlement, 7.6 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is SEPN's daily short volume?
On 2026-11-02, 182,841 of the 224,052 SEPN shares reported to FINRA were sold short, 81.6% of the day's reported volume. Short volume is a flow for one day, not a position.
Does SEPN have fails to deliver?
The SEC's latest file shows 2,120 SEPN shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are SEPN insiders buying or selling?
Insiders at SEPN reported 8 open-market sells worth $72.2M in the last 90 days and no open-market buys. Latest filing: Bhatt Elizabeth (President and COO) on 2026-10-15.
Have SEPN insiders filed to sell?
15 Form 144 notices on file for SEPN worth $89.1M at the prices reported; 6 in the last 90 days worth $81.5M. Latest: DANIEL LONG filed on 2026-10-01 to sell 10,001 shares ($391K) from 2026-10-01.
Who owns 5% or more of SEPN?
5 holders report 5% or more of SEPN in their latest filing, 4 on Schedule 13D (active intent). The largest reported stake is RA Capital Management, L.P. at 11.8% of the class (5,525,324 shares), filed 2026-08-14 for an event on 2026-08-12.
Which tracked 13F managers own SEPN?
6 of the 30 tracked 13F managers held SEPN shares at their latest filing, $12.8M in all. The largest: Two Sigma Investments (221K shares, $7.4M), Izzy Englander's Millennium Management (51K shares, $1.7M), D. E. Shaw & Co. (46K shares, $1.6M), Renaissance Technologies (41K shares, $1.4M), Cliff Asness's AQR Capital Management (15K shares, $516K), Ken Griffin's Citadel Advisors (6K shares, $213K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.